Navigation Links
Researchers attack tumor cells by exploiting dependency on sugar metabolism

Although scientists have known for nearly 90 years that cancer cells commonly display altered sugar metabolism, the molecular significance of this phenomenon is not completely understood. Now, a new study published in the June issue of Cancer Cell reveals a functional connection between carbohydrate-driven energy production and tumor maintenance. Importantly, the results suggest that inhibition of a specific aspect of glucose metabolism may represent an attractive and potentially well-tolerated approach to interfering with tumor growth.

Normal cells produce most of the ATP they need to power cellular functions through an oxygen-dependent process known as oxidative phosphorylation. In contrast, cancer cells commonly switch to what is known as a "glycolytic phenotype," producing ATP through a process that can occur in the absence of oxygen and involves conversion of glucose to lactate. Scientists believe that the glycolytic phenotype enables rapidly proliferating tumor cells to survive even when environmental oxygen levels are not optimal. In addition, perturbations of the normal physiology of mitochondria, cellular structures involved in oxygen-dependent ATP production, have also been linked to cancer.

Dr. Valeria Fantin, formerly of the Department of Genetics at Harvard Medical School, and colleagues examined whether blocking the conversion of glucose to lactate in mammary tumor cells might help shed light on the association between tumor survival and the interplay between glycolytic phenotype and mitochondrial metabolism. The researchers used a sophisticated genetic technique to reduce levels of lactate dehydrogenase A (LDH-A), an enzyme required for the glucose to lactate pathway that is elevated in human breast and lung cancers. Inhibition of LDH-A stimulated mitochondrial function and drastically compromised the ability of the tumor cells to proliferate in low oxygen conditions. Restoration of LDH-A activity reestablished the glycolytic phenotyp e of the tumor cells.

These data suggest that alterations in glucose metabolism in cancer cells are linked with changes in mitochondrial physiology and that LDH-A plays a critical role in tumor growth. The researchers propose that inhibition of LDH-A may represent a rational and safe strategy for treatment of cancer. "Because individuals with complete hereditary deficiency of LDH-A do not show any symptoms under ordinary circumstances, the genetic data suggest that inhibition of LDH-A activity may represent a relatively nontoxic approach to interfere with tumor growth," explains Dr. Fantin.


'"/>

Source:Cell Press


Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. Researchers add new tool to tumor-treatment arsenal
10. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
11. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... announce that Biohaven has issued today the following press ... (PRWEB) Dec 9, 2016 - Biohaven Pharmaceutical Holding ... the U.S. Food and Drug Administration ("FDA") has granted ... candidate BHV-0223, an orally dissolving tablet being developed for ...
(Date:12/8/2016)... -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS ... today announced financial results for the fiscal first ... on our commitment to address an unmet medical ... pleased with the early clinical response data presented ... focused on advancing our lead program – ImmunoPulse® ...
(Date:12/8/2016)... , Dec. 8, 2016 Eurofins announces the appointment ... and President of Eurofins Scientific Inc. (ESI). Mr. ... his proven professional and entrepreneurial experience in leading international business teams. ... US food testing market to uphold Eurofins, status as the global ... ...
(Date:12/8/2016)... BARCELONA, Spain , Dec. 8, 2016  Anaconda ... on the development of the next generation neuro-thrombectomy system ... the appointment of Tudor G. Jovin, MD to join ... to serve as a strategic network of scientific and ... progresses the development of the ANCD BRAIN ® ...
Breaking Biology Technology: